NASDAQ:EXAS - EXACT Sciences Stock Price, Price Target & More

Get Started

$52.01 +0.66 (+1.29 %)

(As of 05/24/2018 10:01 AM ET)

Previous Close$51.32

Today's Range$51.31 - $52.01

52-Week Range$31.04 - $63.60

Volume2,910 shs

Average Volume2.20 million shs

Market Capitalization$6.46 billion

P/E Ratio-52.46

Dividend YieldN/A

Beta0.86

About EXACT Sciences (NASDAQ:EXAS)

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:EXAS

CUSIP30063P10

Webwww.exactsciences.com

Phone608-284-5700

Debt

Debt-to-Equity Ratio0.71

Current Ratio15.30

Quick Ratio14.86

Price-To-Earnings

Trailing P/E Ratio-52.46

Forward P/E Ratio-46.86

P/E GrowthN/A

Sales & Book Value

Annual Sales$265.99 million

Price / Sales23.84

Cash FlowN/A

Price / CashN/A

Book Value$5.64 per share

Price / Book9.22

Profitability

EPS (Most Recent Fiscal Year)($0.99)

Net Income$-114,390,000.00

Net Margins-38.61%

Return on Equity-20.92%

Return on Assets-15.73%

Miscellaneous

Employees1,268

Outstanding Shares121,900,000

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Thursday, April, 26th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.05. The medical research company had revenue of $90.30 million for the quarter, compared to the consensus estimate of $86.31 million. EXACT Sciences had a negative net margin of 38.61% and a negative return on equity of 20.92%. The company's revenue for the quarter was up 86.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.32) EPS. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for EXACT Sciences.

What price target have analysts set for EXAS?

14 equities research analysts have issued 12-month price objectives for EXACT Sciences' stock. Their predictions range from $28.00 to $67.00. On average, they expect EXACT Sciences' share price to reach $54.3846 in the next year. View Analyst Ratings for EXACT Sciences.

Who are some of EXACT Sciences' key competitors?

Some companies that are related to EXACT Sciences include IQVIA (IQV), Incyte (INCY), ICON (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:

Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 52)
Mr. Jeffrey T. Elliott CFA, CFO & Chief Accounting Officer (Age 40)
Mr. Maneesh K. Arora, Sr. VP, COO & Director (Age 49)
Dr. Graham P. Lidgard Ph.D., Chief Science Officer and Sr. VP of R&D (Age 69)
Mr. D. Scott Coward, Chief Legal Officer, Sr. VP, Gen. Counsel and Sec. (Age 53)

Has EXACT Sciences been receiving favorable news coverage?

News coverage about EXAS stock has trended positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. EXACT Sciences earned a news impact score of 0.25 on Accern's scale. They also gave media coverage about the medical research company an impact score of 45.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include LONE PINE CAPITAL LLC (5.30%), OppenheimerFunds Inc. (4.78%), Zevenbergen Capital Investments LLC (1.67%), Eagle Asset Management Inc. (1.46%), Victory Capital Management Inc. (1.40%) and Artisan Partners Limited Partnership (1.23%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which institutional investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Antipodean Advisors LLC, Lord Abbett & CO. LLC, Wasatch Advisors Inc., Rock Springs Capital Management LP, Hodges Capital Management Inc., Prudential Financial Inc., Eagle Asset Management Inc. and California Public Employees Retirement System. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

Which institutional investors are buying EXACT Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Artisan Partners Limited Partnership, Victory Capital Management Inc., Atlantic Trust Group LLC, Elk Creek Partners LLC, Zweig DiMenna Associates LLC, Frontier Capital Management Co. LLC and Intrinsic Edge Capital Management LLC. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson, Katherine S Zanotti, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $52.01.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $6.46 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.

MarketBeat Community Rating for EXACT Sciences (EXAS)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		597 (Vote Outperform)
Underperform Votes:		337 (Vote Underperform)
Total Votes:		934

MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.

EXACT Sciences (NASDAQ:EXAS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

14 Wall Street analysts have issued ratings and price targets for EXACT Sciences in the last 12 months. Their average twelve-month price target is $54.3846, suggesting that the stock has a possible upside of 4.57%. The high price target for EXAS is $67.00 and the low price target for EXAS is $28.00. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.71	2.71	2.57	2.62
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$54.3846	$53.2308	$53.2308	$50.7692
Price Target Upside:	4.57% upside	37.19% upside	18.32% upside	15.90% downside

EXACT Sciences (NASDAQ:EXAS) Consensus Price Target History

Price Target History for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ:EXAS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/29/2018	BTIG Research	Reiterated Rating	Buy	$60.00	High
4/27/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$55.00 ➝ $60.00	High
3/29/2018	William Blair	Reiterated Rating	Buy		N/A
3/28/2018	Leerink Swann	Set Price Target	Buy	$67.00	High
2/27/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$42.56 ➝ $56.00	Medium
2/23/2018	Benchmark	Downgrade	Buy ➝ Hold		High
1/29/2018	Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$17.77 ➝ $51.00	Low
1/8/2018	Bank of America	Set Price Target	Buy	$67.00	High
10/31/2017	Craig Hallum	Boost Price Target	Buy	$46.00 ➝ $61.00	N/A
10/31/2017	Jefferies Group	Boost Price Target	Buy	$60.00	N/A
7/26/2017	Roth Capital	Boost Price Target	Buy	$40.00 ➝ $46.00	High
7/26/2017	Lake Street Capital	Boost Price Target	Hold ➝ Hold	$30.00 ➝ $41.00	Medium
6/7/2017	Stephens	Set Price Target	Hold	$28.00	Medium
5/31/2017	Cowen	Reiterated Rating	Outperform	$45.00	High
7/27/2016	Mizuho	Boost Price Target	Neutral	$10.00 ➝ $15.00	N/A

(Data available from 5/24/2016 forward)

EXACT Sciences (NASDAQ:EXAS) Earnings History and Estimates Chart

Earnings by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ:EXAS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.85)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	($0.33)	($0.24)	($0.27)
Q2 2018	4	($0.33)	($0.18)	($0.24)
Q3 2018	4	($0.32)	($0.10)	($0.20)
Q4 2018	4	($0.31)	($0.03)	($0.15)
Q1 2019	1	($0.14)	($0.14)	($0.14)

EXACT Sciences (NASDAQ EXAS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/23/2018		($0.33)					N/A
4/26/2018	Q1 2018	($0.38)	($0.33)	$86.31 million	$90.30 million	View	N/A
2/22/2018	Q4 2017	($0.27)	($0.18)	$87.42 million	$87.41 million	View	Listen
10/30/2017	Q3 2017	($0.30)	($0.23)	$65.03 million	$72.60 million	View	N/A
7/25/2017	Q2 2017	($0.37)	($0.27)	$47.73 million	$57.65 million	View	N/A
4/27/2017	Q1 2017	($0.41)	($0.32)	$37.38 million	$48.36 million	View	N/A
2/21/2017	Q416	($0.39)	($0.34)	$32.53 million	$35.24 million	View	Listen
10/26/2016	Q316	($0.43)	($0.36)	$25.24 million	$28.10 million	View	Listen
7/26/2016	Q216	($0.55)	($0.46)	$18.54 million	$21.20 million	View	Listen
5/3/2016	Q116	($0.52)	($0.49)	$15.17 million	$14.80 million	View	N/A
2/24/2016	Q415	($0.47)	($0.41)	$14.96 million	$14.40 million	View	Listen
10/29/2015	Q315	($0.44)	($0.45)	$12.56 million	$12.60 million	View	Listen
7/20/2015	Q215	($0.45)	($0.44)	$7.96 million	$8.10 million	View	Listen
5/4/2015	Q115	($0.41)	($0.40)	$4.11 million	$4.30 million	View	N/A
2/24/2015	Q414	($0.39)	($0.38)	$19.90 million	$1.15 million	View	N/A
10/27/2014	Q314	($0.34)	($0.39)	$0.13 million		View	Listen
7/22/2014	Q214	($0.25)	($0.24)	$0.03 million		View	N/A
5/1/2014	Q114	($0.19)	($0.23)	$0.40 million	$0.30 million	View	N/A
2/20/2014	Q413	($0.19)	($0.17)	$1.02 million	$1.00 million	View	N/A
10/29/2013	Q313	($0.18)	($0.16)	$1.02 million	$1.00 million	View	N/A
7/23/2013	Q2 2013	($0.18)	($0.19)	$1.02 million	$1.00 million	View	N/A
5/1/2013	Q1 2013	($0.20)	($0.17)	$1.02 million	$1.00 million	View	N/A
2/20/2013	Q4 2012	($0.18)	($0.22)	$1.04 million	$1.00 million	View	N/A
10/30/2012	Q312	($0.21)	($0.21)	$1.03 million	$1.04 million	View	N/A
7/25/2012		($0.20)	($0.26)			View	N/A
5/1/2012		($0.18)	($0.19)			View	N/A
2/23/2012		($0.17)	($0.18)			View	N/A
11/3/2011		($0.15)	($0.15)			View	N/A
8/2/2011		($0.10)	($0.13)			View	N/A
5/3/2011		($0.09)	($0.08)			View	N/A
2/15/2011		($0.08)	($0.08)			View	N/A
10/27/2010	Q3 2010	($0.08)	($0.08)			View	N/A
7/28/2010	Q2 2010	($0.07)	($0.06)			View	N/A
5/6/2010	Q1 2010	($0.05)	($0.06)			View	N/A
2/16/2010	Q4 2009	($0.06)	($0.05)			View	N/A
11/3/2009	Q3 2009		($0.03)			View	N/A
8/12/2009	Q2 2009		($0.08)			View	N/A
5/5/2009	Q1 2009		($0.13)			View	N/A
3/30/2009	Q4 2008		($0.08)			View	N/A
11/6/2008	Q3 2008		($0.09)			View	N/A
8/7/2008	Q2 2008		($0.08)			View	N/A
5/5/2008	Q1 2008		($0.09)			View	N/A
2/4/2008	Q4 2007		($0.14)			View	N/A

(Earnings results data provided by Zacks Investment Research)

EXACT Sciences (NASDAQ:EXAS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

EXACT Sciences (NASDAQ EXAS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 88.72%

Insider Trading History for EXACT Sciences (NASDAQ:EXAS)

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ EXAS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2018	Michael S Wyzga	Director	Sell	7,402	$51.53	$381,425.06	10,974
4/12/2018	Katherine S Zanotti	Director	Sell	7,232	$45.00	$325,440.00	105,814
4/10/2018	Thomas D Carey	Director	Sell	8,448	$39.73	$335,639.04	52,610
4/2/2018	D Scott Coward	SVP	Sell	2,122	$40.12	$85,134.64
3/12/2018	D Scott Coward	SVP	Sell	2,708	$52.19	$141,330.52
3/12/2018	Kevin T Conroy	Insider	Sell	11,459	$52.19	$598,045.21	200,074
3/12/2018	Maneesh Arora	COO	Sell	5,295	$52.19	$276,346.05
3/9/2018	Graham Peter Lidgard	Insider	Sell	6,125	$50.94	$312,007.50	200,074
2/28/2018	Graham Peter Lidgard	Insider	Sell	39,884	$43.10	$1,719,000.40
2/26/2018	D Scott Coward	SVP	Sell	4,420	$42.34	$187,142.80
2/26/2018	Jeffrey Thomas Elliott	CFO	Sell	2,982	$42.34	$126,257.88
2/26/2018	Kevin T Conroy	Insider	Sell	25,319	$42.34	$1,072,006.46	211,183
2/26/2018	Maneesh Arora	COO	Sell	12,352	$42.34	$522,983.68	644,621
2/9/2018	Kevin T Conroy	Insider	Sell	101,488	$45.72	$4,640,031.36	931,540
1/23/2018	Kevin T Conroy	Insider	Sell	110,439	$50.49	$5,576,065.11	940,491
1/12/2018	Kevin T Conroy	Insider	Sell	125,402	$52.79	$6,619,971.58	955,454
1/3/2018	D Scott Coward	SVP	Sell	1,665	$52.54	$87,479.10	37,558
12/22/2017	Kevin T Conroy	Insider	Sell	123,512	$52.58	$6,494,260.96	953,564
12/6/2017	Kevin T Conroy	Insider	Sell	121,849	$53.45	$6,512,829.05	951,901
12/1/2017	Graham Peter Lidgard	Insider	Sell	45,770	$58.27	$2,667,017.90	237,820
11/21/2017	Kevin T Conroy	Insider	Sell	134,057	$59.50	$7,976,391.50
11/9/2017	Kevin T Conroy	CEO	Sell	137,805	$59.14	$8,149,787.70	967,867
11/1/2017	Graham Peter Lidgard	Insider	Sell	45,775	$53.60	$2,453,540.00	272,819
10/2/2017	D Scott Coward	SVP	Sell	29,115	$47.16	$1,373,063.40	64,991
10/2/2017	Graham Peter Lidgard	Insider	Sell	81,025	$47.16	$3,821,139.00	366,519
9/5/2017	Graham Peter Lidgard	Insider	Sell	75,683	$40.81	$3,088,623.23	308,377
9/1/2017	Graham Peter Lidgard	Insider	Sell	45,775	$41.49	$1,899,204.75	288,952
8/17/2017	Thomas D Carey	Director	Buy	2,500	$37.71	$94,275.00	60,858
7/31/2017	Jeffrey Thomas Elliott	CFO	Sell	5,846	$39.41	$230,390.86	19,861
7/3/2017	D Scott Coward	SVP	Sell	1,987	$35.21	$69,962.27	57,603
4/3/2017	D Scott Coward	SVP	Sell	1,543	$23.74	$36,630.82	55,478
3/13/2017	D Scott Coward	SVP	Sell	1,983	$21.16	$41,960.28	50,790
3/13/2017	Kevin T Conroy	Insider	Sell	12,059	$21.16	$255,168.44	817,239
3/13/2017	Maneesh Arora	COO	Sell	5,574	$21.16	$117,945.84	556,339
2/27/2017	D Scott Coward	SVP	Sell	7,046	$21.48	$151,348.08	53,794
2/27/2017	Graham Peter Lidgard	Insider	Sell	8,668	$21.51	$186,448.68	314,527
2/27/2017	Maneesh Arora	COO	Sell	11,114	$21.50	$238,951.00	535,940
1/3/2017	D Scott Coward	SVP	Sell	1,535	$13.61	$20,891.35	29,242
12/14/2016	David Thompson	Director	Buy	10,000	$13.84	$138,400.00	136,379
11/15/2016	Kevin T Conroy	Insider	Sell	600,000	$17.46	$10,476,000.00	1,340,057
11/15/2016	Maneesh Arora	COO	Sell	562,932	$17.46	$9,828,792.72	1,094,309
9/1/2016	Lionel Sterling	Director	Buy	5,000	$18.10	$90,500.00	121,247
8/3/2016	Katherine S Zanotti	Director	Buy	3,380	$17.93	$60,603.40	105,927
7/26/2016	Graham Peter Lidgard	Insider	Sell	7,383	$14.82	$109,416.06	227,592
7/26/2016	Maneesh Arora	COO	Sell	7,359	$14.82	$109,060.38	538,736
4/1/2016	D Scott Coward	SVP	Sell	1,685	$6.62	$11,154.70	21,014
3/10/2016	D Scott Coward	SVP	Sell	2,175	$6.05	$13,158.75	18,501
3/10/2016	Graham Peter Lidgard	Insider	Sell	3,041	$6.05	$18,398.05	228,170
3/10/2016	Maneesh Arora	COO	Sell	4,042	$6.05	$24,454.10	273,210
3/8/2016	James Edward Doyle	Director	Buy	5,000	$6.43	$32,150.00	21,459
3/3/2016	Katherine S Napier	Director	Buy	3,775	$5.38	$20,309.50	91,000
3/1/2016	Kevin T Conroy	CEO	Buy	50,000	$5.00	$250,000.00	687,907
2/26/2016	Kevin T Conroy	CEO	Sell	6,895	$5.81	$40,059.95	637,907
2/25/2016	Graham Peter Lidgard	Insider	Sell	2,997	$5.52	$16,543.44	222,742
2/25/2016	Maneesh Arora	COO	Sell	4,099	$5.52	$22,626.48	266,034
2/23/2016	Graham Peter Lidgard	Insider	Sell	2,411	$6.39	$15,406.29	216,903
2/23/2016	Kevin T Conroy	CEO	Sell	6,866	$6.39	$43,873.74	632,168
2/23/2016	Maneesh Arora	COO	Sell	2,556	$6.39	$16,332.84	257,590
1/11/2016	David Thompson	Director	Buy	15,000	$6.99	$104,850.00	110,213
2/26/2015	Graham Peter Lidgard	Director	Sell	3,938	$23.44	$92,306.72
2/26/2015	Kevin T Conroy	CEO	Sell	8,425	$23.44	$197,482.00
2/26/2015	Maneesh Arora	COO	Sell	3,895	$23.44	$91,298.80
2/24/2015	Graham Peter Lidgard	Director	Sell	4,037	$22.90	$92,447.30
2/24/2015	Kevin T Conroy	CEO	Sell	9,798	$22.90	$224,374.20
2/24/2015	Maneesh Arora	COO	Sell	2,995	$22.90	$68,585.50
1/2/2015	Graham Peter Lidgard	Insider	Sell	3,363	$26.72	$89,859.36
1/2/2015	Kevin T Conroy	CEO	Sell	9,484	$26.72	$253,412.48
1/2/2015	Maneesh Arora	COO	Sell	2,495	$26.72	$66,666.40
10/29/2014	Graham Peter Lidgard	Insider	Sell	8,015	$24.68	$197,810.20
7/25/2014	Graham Peter Lidgard	VP	Sell	11,081	$15.99	$177,185.19
7/25/2014	Kevin T Conroy	CEO	Sell	11,336	$15.99	$181,262.64
7/25/2014	Maneesh Arora	COO	Sell	9,291	$15.99	$148,563.09
5/5/2014	William Megan	SVP	Buy	10,000	$11.79	$117,900.00	12,522
2/24/2014	Graham Peter Lidgard	VP	Sell	3,160	$14.07	$44,461.20	106,214
2/24/2014	Kevin Conroy	CEO	Sell	8,708	$14.07	$122,521.56	134,374
2/24/2014	Maneesh Arora	COO	Sell	2,662	$14.07	$37,454.34	65,855
1/2/2014	Graham Peter Lidgard	VP	Sell	10,288	$11.96	$123,044.48	102,149
1/2/2014	Kevin Conroy	CEO	Sell	26,379	$11.96	$315,492.84	123,707
1/2/2014	Maneesh Arora	COO	Sell	8,627	$11.96	$103,178.92	61,292
10/28/2013	Graham Peter Lidgard	VP	Sell	7,430	$11.07	$82,250.10
9/20/2013	Sally Crawford	Director	Sell	25,000	$12.19	$304,750.00	203,866
11/2/2012	Kevin T Conroy	CEO	Buy	2,000	$9.13	$18,260.00
11/2/2012	Maneesh Arora	CFO	Buy	1,000	$9.04	$9,040.00
11/1/2012	Lionel Sterling	Director	Buy	5,500	$9.08	$49,940.00

(Data available from 1/1/2013 forward)

EXACT Sciences (NASDAQ EXAS) News Headlines

Source:

Date	Headline
	$103.93 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter www.americanbankingnews.com - May 24 at 4:32 AM
	Freenome Sets Sights On Blood Test To Detect Colon Cancer www.forbes.com - May 23 at 8:17 AM
	Syneos Health (SYNH) & EXACT Sciences (EXAS) Head-To-Head Survey www.americanbankingnews.com - May 22 at 9:16 PM
	Zacks: Brokerages Expect EXACT Sciences Co. (EXAS) to Post -$0.32 Earnings Per Share www.americanbankingnews.com - May 22 at 9:40 AM
	Contrasting EXACT Sciences (EXAS) and BTG (BTGGF) www.americanbankingnews.com - May 18 at 1:08 AM
	EXACT Sciences Co. (EXAS) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - May 14 at 5:30 PM
	4 Biotech Stocks Set to Rise By 14% or More finance.yahoo.com - May 14 at 8:25 AM
	EXACT Sciences Co. (EXAS) Director Michael S. Wyzga Sells 7,402 Shares www.americanbankingnews.com - May 11 at 7:58 PM
	Zacks: Analysts Anticipate EXACT Sciences Co. (EXAS) Will Announce Quarterly Sales of $103.93 Million www.americanbankingnews.com - May 7 at 5:55 AM
	EXACT Sciences Co. (EXAS) Expected to Announce Earnings of -$0.32 Per Share www.americanbankingnews.com - May 5 at 1:17 AM
	EXACT Sciences (EXAS) Lifted to Strong-Buy at ValuEngine www.americanbankingnews.com - May 4 at 12:13 AM
	Exact Sciences teams with Vince Lombardi foundation in fight against colon cancer finance.yahoo.com - May 3 at 5:26 PM
	Vince Lombardi Cancer Foundation and Exact Sciences Team Up to Fight Colon Cancer finance.yahoo.com - May 3 at 5:26 PM
	Exact Sciences: A Big Opportunity? www.msn.com - May 2 at 5:38 PM
	[$$] Exact Sciences: A Big Opportunity? finance.yahoo.com - May 2 at 5:38 PM
	Must See Stock Score Reports for Charter Communications, Exact Sciences, Nike ... www.prnewswire.com - May 1 at 8:23 AM
	Must See Stock Score Reports for Charter Communications, Exact Sciences, Nike, Sprint, and Snap Inc. www.bizjournals.com - April 30 at 5:15 PM
	Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher www.zacks.com - April 30 at 8:22 AM
	EXACT Sciences (EXAS) Earns Buy Rating from BTIG Research www.americanbankingnews.com - April 29 at 9:17 AM
	EXACT Sciences (EXAS) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 27 at 10:18 PM
	Why SVB Financial Group, Exact Sciences, and Sprint Jumped Today finance.yahoo.com - April 27 at 5:16 PM
	EXACT Sciences (EXAS) Stock Rating Reaffirmed by Canaccord Genuity www.americanbankingnews.com - April 27 at 11:27 AM
	Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact ... www.benzinga.com - April 27 at 8:29 AM
	BRIEF-Exact Sciences reports Q1 Loss Per Share of $0.33 www.reuters.com - April 27 at 8:29 AM
	Form 10-Q EXACT SCIENCES CORP For: Mar 31 www.streetinsider.com - April 27 at 8:29 AM
	EXACT Sciences (EXAS) Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 27 at 8:29 AM
	Exact Sciences revenue jumps 87% in first quarter, topping consensus finance.yahoo.com - April 27 at 8:29 AM
	Exact Sciences: 1Q Earnings Snapshot finance.yahoo.com - April 27 at 8:29 AM
	EXACT Sciences (EXAS) Issues Quarterly Earnings Results www.americanbankingnews.com - April 26 at 11:32 PM
	Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000 finance.yahoo.com - April 26 at 5:18 PM
	Don't Get Greedy With Exact Sciences Corporation Stock finance.yahoo.com - April 25 at 8:19 AM
	Don't Get Greedy With Exact Sciences Corporation Stock finance.yahoo.com - April 25 at 8:19 AM
	EXACT Sciences (EXAS) Lifted to Strong-Buy at Vetr www.americanbankingnews.com - April 20 at 10:18 PM
	EXACT Sciences (EXAS) Upgraded to "Buy" by BidaskClub www.americanbankingnews.com - April 20 at 11:39 AM
	EXACT Sciences Co. (EXAS) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 19 at 5:40 PM
	EXACT Sciences (EXAS) Stock Rating Lowered by Vetr www.americanbankingnews.com - April 19 at 9:23 AM
	EXACT Sciences (EXAS) Scheduled to Post Earnings on Thursday www.americanbankingnews.com - April 19 at 2:34 AM
	$86.09 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter www.americanbankingnews.com - April 19 at 1:54 AM
	BTIG Research Reaffirms "Buy" Rating for EXACT Sciences (EXAS) www.americanbankingnews.com - April 17 at 11:58 PM
	Zacks: Analysts Expect EXACT Sciences Co. (EXAS) Will Announce Earnings of -$0.39 Per Share www.americanbankingnews.com - April 17 at 11:08 PM
	EXACT Sciences Breaks Above 200-Day Moving Average - Bullish for EXAS www.nasdaq.com - April 17 at 5:56 PM
	Lake Street Capital Raises EXACT Sciences (EXAS) Price Target to $41.00 www.americanbankingnews.com - April 15 at 8:54 PM
	EXACT Sciences (EXAS) Upgraded at Vetr www.americanbankingnews.com - April 14 at 1:27 PM
	Vetr Lowers EXACT Sciences (EXAS) to Hold www.americanbankingnews.com - April 14 at 12:17 AM
	Insider Selling: EXACT Sciences Co. (EXAS) Director Sells 7,232 Shares of Stock www.americanbankingnews.com - April 13 at 10:10 PM
	Short Interest in EXACT Sciences Co. (EXAS) Decreases By 10.5% www.americanbankingnews.com - April 13 at 3:43 AM
	Thomas D. Carey Sells 8,448 Shares of EXACT Sciences Co. (EXAS) Stock www.americanbankingnews.com - April 12 at 4:33 PM
	Noteworthy Tuesday Option Activity: GM, EXAS, TMUS www.nasdaq.com - April 10 at 5:30 PM
	Today’s Research Reports on Trending Tickers: Exact Sciences and Exelixis finance.yahoo.com - April 10 at 8:25 AM
	Exact Sciences schedules first-quarter 2018 earnings call finance.yahoo.com - April 9 at 8:18 AM

EXACT Sciences (NASDAQ:EXAS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

EXACT Sciences (NASDAQ:EXAS) Income Statement, Balance Sheet and Cash Flow Statement

EXACT Sciences (NASDAQ EXAS) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff